Payment overview · 2025
General Payments
$1,431.35
75 reported records · 21 companies
Healthcare provider profile · identity verified
John Wilson Boggess, MD
Allopathic & Osteopathic Physicians|General Practice · GUNTERSVILLE, AL · NPI 1699731935
Verified facts
What the public records show
CMS Open Payments records show John Wilson Boggess, MD received $1,431.35 in general payments during 2025 across 75 reported records.
ABBVIE INC. accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $266.56 | 18.6% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.19 | 12.2% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $137.38 | 9.6% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.34 | 8.7% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $117.77 | 8.2% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $95.44 | 6.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.78 | 5.8% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.70 | 4.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.67 | 3.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.21 | 3.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.18 | 3.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.42 | 3.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.21 | 2.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.31 | 1.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.33 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.21 | 1.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.94 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.45 | 1.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.18 | 1.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.59 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.49 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,431.35 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $137.38 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $130.87 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.34 | 5 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $121.08 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $117.77 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.34 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.78 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $73.88 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.58 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.99 | 3 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $56.06 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.67 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.08 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.18 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.18 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $42.42 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.21 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.86 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | ABBVIE INC. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 31 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 113 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 528 | 75 |
| Omeprazole | Omeprazole | 523 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 111 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 455 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 452 | 113 |
| Losartan Potassium | Losartan Potassium | 309 | 75 |
| Temazepam | Temazepam | 294 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 288 | 59 |
| Furosemide | Furosemide | 242 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 65 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 28 |
| Tramadol Hcl | Tramadol Hcl | 217 | 51 |
| Trazodone Hcl | Trazodone Hcl | 208 | 39 |
| Metformin Hcl | Metformin Hcl | 191 | 46 |
| Cefdinir | Cefdinir | 179 | 136 |
| Methocarbamol | Methocarbamol | 177 | 59 |
| Lisinopril | Lisinopril | 176 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 39 |
| Potassium Chloride | Potassium Chloride | 170 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 36 |
| Gabapentin | Gabapentin | 163 | 36 |
| Meloxicam | Meloxicam | 162 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 161 | 41 |
| Clonazepam | Clonazepam | 148 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 27 |
| Valsartan | Valsartan | 136 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 133 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 131 | 33 |
| Pregabalin | Pregabalin | 130 | 25 |
| Celecoxib | Celecoxib | 128 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 37 |
| Naproxen | Naproxen | 115 | 33 |
| Mounjaro | Tirzepatide | 113 | 16 |
| Prednisone | Prednisone | 113 | 68 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 110 | 21 |
| Cephalexin | Cephalexin | 105 | 59 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 105 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 34 |
| Ozempic | Semaglutide | 104 | 16 |
| Azithromycin | Azithromycin | 103 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 26 |
| Eliquis | Apixaban | 99 | 20 |
| Atenolol | Atenolol | 98 | 23 |
| Fluconazole | Fluconazole | 98 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 22 |
| Simvastatin | Simvastatin | 92 | 24 |
| Allopurinol | Allopurinol | 89 | 20 |
| Donepezil Hcl | Donepezil Hcl | 86 | 19 |
| Meclizine Hcl | Meclizine Hcl | 81 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 79 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 29 |
| Farxiga | Dapagliflozin Propanediol | 71 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 13 |
| Glimepiride | Glimepiride | 67 | 19 |
| Spironolactone | Spironolactone | 67 | 15 |
| Buspirone Hcl | Buspirone Hcl | 62 | 13 |
| Estradiol | Estradiol | 61 | 14 |
| Methylprednisolone | Methylprednisolone | 60 | 53 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 60 | 39 |
| Lorazepam | Lorazepam | 59 | 18 |
| Montelukast Sodium | Montelukast Sodium | 58 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 29 |
| Jardiance | Empagliflozin | 55 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 21 |
| Carvedilol | Carvedilol | 53 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 11 |
| Synthroid | Levothyroxine Sodium | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 33 |
| Mupirocin | Mupirocin | 50 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Ibuprofen | Ibuprofen | 46 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 26 |
| Promethazine Hcl | Promethazine Hcl | 41 | 13 |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 28 |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 23 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Cefprozil | Cefprozil | 34 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Carisoprodol | Carisoprodol | 32 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Premarin | Estrogens, Conjugated | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Nystatin | Nystatin | 30 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 27 | 18 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | 11 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Betaseron | Interferon Beta-1b | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,431.35 · 75 records | ABBVIE INC. | ABRYSVO, AVYCAZ, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, EMBLAVEO, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, IBSRELA, INSPIRE, JARDIANCE, KEVEYIS, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, REXULTI, Rybelsus, TEFLARO, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error